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Introduction
▼
There are limitations to the cytological diagnosis 
of thyroid nodules, especially follicular lesions. 
Differential diagnosis between the follicular-pat-
terned thyroid lesions is often difficult to deter-
mine, even for the most experienced pathologists 
[1–3]. A precise pathological diagnosis is critical 
for effective clinical management in these cases 
and guides complete thyroidectomy and neck 
exploration after a diagnosis of malignancy based 
on thyroid lobectomies. Most papillary thyroid 
carcinoma (PTC) cases show low rates of recur-
rence and good prognosis based on long term 
follow-up [4, 5]. However, some cases have a poor 
prognosis including patients over 45 years old 
with BRAF-positive mutations; furthermore, 
these patients might become insensitive to radi-
oiodine therapy [2, 5–7]. Studying molecules that 
are differentially expressed between cancers as 
well as benign and normal tissues is crucial for 
identifying novel biomarkers for cancer immuno-
therapy. Thus, methods that could accurately dis-
tinguish benign thyroid lesions from differentiated 
thyroid carcinomas (DTC) are greatly desired.
The carcinogenesis process is related to an accu-
mulation of neoplastic cells due to increased cell 
production or decreased cell death [8]. Ki-67 is a 
cell proliferation protein that is recognized as a 
neoplastic marker that is studied in different tis-
sues and is related to poor prognosis based on 
DTC follow-up [9–16]. According to Miyauchi et 
al. [9], a Ki-67 labeling index of more than 10 %, 
which is considered to be strong expression in 
PTC cases, is associated with persistent biochem-
ical disease (positive thyroglobulin) representing 
a poor prognosis criterion. Some authors believe 
that Ki-67 may help distinguish thyroid follicular 
Abstract
▼
Studying molecules that are differentially 
expressed in cancers as well as benign and nor-
mal tissues is crucial for identifying novel bio-
markers for cancer immunotherapy. This study 
aimed to investigate the clinical utility of the 
immunochemical expression of the prolifera-
tive cell marker Ki-67 and the apoptotic blocker 
Mcl-1 in papillary thyroid carcinoma (PTC).
Methods: We built a tissue microarray with 
282 thyroid specimens. There were 59 PTCs 
including 35 classic (CPTC), 3 tall cell (TCPTC) 
and 21 follicular variants (FVPTC); 79 benign 
thyroid diseases (22 follicular adenomas; 57 
adenomatoid hyperplasia); 33 Hashimoto’s thy-
roiditis (HT) specimens; and 111 normal thyroid 
tissues. Clinical history and ultrasound data were 
retrospectively obtained by chart review.
Results: Mcl-1 overexpression was evident 
in 66.7 % of the PTC tissues compared to 32 % 
of the benign thyroid diseases. Mcl-1 strong 
staining distinguished benign from malignant 
thyroid lesions (sensitivity = 61.3 %; specific-
ity = 72.8 %; negative predictive value, NPV = 68 %; 
positive predictive value, PPV = 66.7 % and 67.5 % 
accuracy). Positive nuclear Ki-67 staining was 
observed in 34 % of PTCs vs. 19 % of thyroid ade-
nomas (P = 0.031). Strong Mcl-1 and Ki-67 co-
expression was identified in 57.5 % of PTCs with a 
higher PPV (75.8 %). Mcl-1 and Ki-67 expression 
was not associated with any clinicopathological 
feature of malignancy. No deaths occurred dur-
ing the follow-up.
Conclusions: Mcl-1 immunochemical overex-
pression allowed differentiating low-risk PTC 
from the benign thyroid lesions. We suggest that 
Mcl-1 expression may help differentiate follicular 
patterned thyroid lesions. The influence of the 
Mcl-1 expression on several features of tumor 
aggressiveness has to be studied in large series of 
high-risk thyroid carcinomas. D
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adenomas (TFAs) from PTC [9, 10, 12–14]; however, the follicular 
carcinoma results are still controversial [10, 11, 15]. Tallini et al. 
[14] found a poor prognosis related to Ki-67 overexpression in 
90 DTC patients, particularly in cases of papillary or follicular 
carcinomas with unfavorable pathologic features.
On the other hand, in the carcinogenesis process, many molecu-
lar markers are involved in apoptosis control, such as Bcl-2 
(B-cell lymphoma), Mcl-1 (myeloid cell leukemia-1), Fas/FasL, 
p53, and p21 [17–20]. Mcl-1 is an anti-apoptotic member of the 
Bcl-2 family that has been implicated in tumor cell death and cell 
survival and confers chemotherapeutic resistance [20, 21]. In 
1996, Branet et al. [22] studied Mcl-1 immunochemical (IHQ) 
staining in 23 PTC specimens compared to 12 TFA tissue sam-
ples. They concluded that Bcl-2 family genes contribute to the 
pathogenesis of thyroid carcinomas. Over the last two decades, 
there have been limited data related to Mcl-1 protein expression 
in different thyroid tissues and the impact of the expression lev-
els on the clinical prognosis in PTC [18, 22]. However, Mcl-1 
expression has been shown to be a poor prognostic marker in 
other solid tumors, such as breast, cervical, colon, ovarian, and 
gastric cancers [20, 23–26]. Moreover, there is evidence of the 
involvement of Mcl-1 protein and its association with Ki-67 
expression resulting in poor prognosis, as demonstrated in cer-
vical cancer [23].
Previous reports revealed the potential benefits of combined 
malignancy markers such as cytokeratin 19 (CK-19), galectin-3 
(Gal-3), HBME-1 (Hector Battifora Mesothelial cell), FoxP3 (Fork-
head box P3), KAP-1 and mucin-1 (MUC-1) protein for routine 
thyroid pathology, which enhances the accuracy of the malig-
nancy diagnosis [27–31]. However, further analysis is still 
required to evaluate the potential clinical use of these markers. 
The role of the apoptotic blocker, Mcl-1 protein, in the pathogen-
esis of thyroid carcinomas, TFAs, adenomatoid hyperplasia and 
HT is not well established in the present literature.
This study aimed to investigate the immunochemical expression 
of Ki-67 and Mcl-1 in routine histological evaluation in a large 
cohort of benign and malign thyroid lesions. Clinical history and 
sonographic information were also obtained by chart review, 
and these were correlated to the expression these markers.
Materials and Methods
▼
Patients
The institutional review board approved the study, and no com-
peting financial interests exist. We investigated 140 thyroid can-
cer patients and 4 controls who underwent thyroidectomy 
between 2000 and 2013 whose specimens were maintained in 
the tissue bank of the General Hospital of the University of 
Campinas, which is an iodine sufficient area in Brazil. This study 
included 282 thyroid samples: 59 PTC specimens; 2 medullary 
thyroid carcinomas (MTC) were excluded at final analysis; 79 
benign thyroid diseases (22 TFA; 57 adenomatoid hyperplasia 
tissues), 111 normal thyroid (107 adjacent peri-tumoral tissues 
plus 4 control cases) and 33 HT samples. The malignant speci-
mens were classified as follows: 35 classic (CPTC), 3 tall cell 
(TCPTC), and 21 follicular PTC variants (FVPTC). Clinical history, 
laboratory, cytological and sonographic information was 
obtained by chart review. The clinical diagnosis of HT was con-
firmed based on high levels of serum antithyroperoxidase and 
antithyroglobulin antibodies.
Tissue specimens
We selected 10 % formalin-fixed, paraffin-embedded blocks that 
are routinely prepared from the surgical specimens of 142 thy-
roidectomies. Histologically normal thyroid tissue samples adja-
cent to tumors obtained from thyroid surgery were used as 
controls. We used tissue arrays containing 282 thyroid samples 
as previous described. Two independent, blinded observers 
reviewed all of the thyroid slides to confirm the histopathologi-
cal diagnosis based on the World Health Organization (WHO) 
histological classification and Livolsi’s classification of thyroid 
pathology [32, 33]. All malignant tumors were classified based 
on the American Joint Committee on Cancer classification sys-
tem of pTNM parameters and age [34]. Surgery was indicated 
based on cytological results or when nodules were benign but 
caused compressive symptoms (16.8 %).
Immunohistochemistry
Surgical specimens were fixed in 10 % buffered formalin and 
embedded in paraffin. Tissue sections, 0.5 mm thick, were 
deparaffinized in xylene and dehydrated in a graded ethanol 
series. Endogenous peroxidase activity and nonspecific binding 
were blocked with 0.3 % hydrogen peroxide in methanol for 
15 min. After rinsing in phosphate-buffered saline at a pH of 7.2, 
10 % bovine serum (Wako, Osaka, Japan) was applied for 20 min 
to block nonspecific reactions. Sections were then incubated 
with primary antibody overnight at 4 °C. A single pathologist 
expert in thyroid field selected 2 samples of the most represent-
ative areas each of the nodular and peritumoral tissues, 1 mm in 
size, for the tissue microarray. The sections were then incubated 
with the primary high specificity antibodies as follows: mono-
clonal Mcl-1 antibody (Rabbit, Ab-32087; Abcam, Cambridge, 
USA; diluted 1:50) and Ki-67 monoclonal antibody (clone MIB-
1, M724001–2, Dako, CA, USA; diluted 1:500). A second-genera-
tion peroxidase-based, biotin-free polymer detection system 
(Advance, Dako) was used to visualize the antigen-antibody 
reaction. Positive and negative control tissues were included to 
ensure the specificity and reliability of the stains as follows: 
lymph nodes for Ki-67 and tonsils for Mcl-1, based on the manu-
facturer’s recommendations. The monoclonal anti-Mcl-1 anti-
body does not cross-react with other Bcl-2 family members, 
which enhances the high specificity. The anti-Mcl-1 antibody 
detects a long chain Mcl-1 protein (37 kDa) called isoform 1, 
which is recognized as an anti-apoptotic protein [35, 36]. Nega-
tive controls were obtained by replacing the primary antibody 
with non-immune serum, as previously described [20, 22, 25].
Immunohistochemical evaluation
All analyses were performed on a light microscope (Eclipse 
E200, Nikon Instruments Inc., NY, USA). Two independent 
observers who were blinded to the histological results scored all 
of the slides, and cases with inconsistent scores were reevalu-
ated to achieve a consensus score. Mcl-1-positive staining was 
defined as brown staining in the cytoplasm of thyroid cells; the 
immunostaining of the follicular colloid in the absence of stain-
ing of the follicular epithelium or cytoplasm was considered 
nonspecific and negative. For Ki-67, the homogeneously stained 
nuclei indicated a positive result. The immunostaining of the fol-
licular colloid in the absence of staining of the follicular epithe-
lium or cytoplasm was considered to be nonspecific and 
negative. Visual IHC and a semiquantitative approach were used 
with different cut-offs for each marker, depending on the extent 
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of expression, by calculating the percentage of immunoreactive 
cells on a minimum of 500 cells [20, 25]. Evaluation included the 
proportion of reactive cells within tumors as well as the staining 
intensity. Sections were scanned at low power to identify areas 
that were evenly labeled, and an estimate of positive results 
with the Mcl-1 antibody was scored as follows: 0 %, negative 
(grade 0); 1–19 %, 1 + (grade 1); and over 20 %, 2 + (grade 2). The 
IHQ overexpression results defined the anti-apoptotic Mcl-1 sta-
tus as previously reported [20, 25]. The intensity of the Ki-67 
nuclei staining was scored on a 4 point scale: 0 %, no stain-
ing; < 1 % (weak staining); 1–2 % (clear staining); and > 2 % (robust 
positive staining). Clear and robust expression (> 1 %) was con-
sidered strong positivity [10, 15].
Statistical analysis
Histologic results were used as the standard reference. Sensitiv-
ity, specificity, negative and positive predictive values (NPV; PPV, 
respectively) and accuracy were also calculated based on histo-
logical results, with Mcl-1 protein overexpression as positive 
and weak or undetected Mcl-1 protein expression as negative. A 
multivariate logistic regression model was applied to correlate 
Mcl-1 expression with the Ki-67 immunochemical marker and 
the clinical and US data. The results were analyzed by chi-square 
test or Fisher’s exact test for categorical variables and Mann-
Whitney test for the quantitative variables of benign and malign 
nodules. All of the tests were performed using Statistical Analy-
sis System (SAS) for Windows, version 9.4 (SAS Institute Inc., 
Cary, NC, USA), at a 0.05 significance level.
Results
▼
The histological findings in the 138 thyroidectomies (4 control 
cases excluded) identified 59 (42.8 %) malignant cases and 79 
(57.2 %) benign thyroid diseases. The clinical and laboratory data 
did not reveal any significant differences between the malignant 
and benign nodules, especially related to gender, TSH levels, thy-
roid auto-immunity markers, cold nodule, and size over 2 cm. 
Two or more suspicious US parameters (hypoechogenicity, irreg-
ular margins, microcalcifications, taller than wide, capsule inva-
sion, central flow predominance) were strongly correlated with 
malignancy (P < 0.001). Indeterminate cytological results were 
found in 55.8 % of cases (77/138: 43 classified as Bethesda III; 14, 
as Bethesda IV; 20, as Bethesda V).
Immunohistochemical analyses
The immunostaining results of apoptotic and proliferative cell 
markers in neoplastic and noncancerous thyroid lesions are 
summarized in  ●▶  Table 1. The final tumor stages for all 59 PTCs 
according to TNM classification showed 86.4 % of tumors in stage 
I or II and 13.6 % in stage III or IV. The predominant TNM result 
was T1–2, N0, M0.
The expression profile of Mcl-1 in human thyroid cancer, benign 
thyroid disease and normal tissue
Mcl-1 overexpression was evident in 66.7 % of the PTC speci-
mens compared to 32 % of benign thyroid diseases ( ●▶  Fig. 1, 
P = 0.003). Mcl-1 strong staining distinguished benign from 
malign thyroid lesions with 67.5 % accuracy (sensitivity = 61.3 %; 
specificity = 72.8 %; negative predictive value, NPV = 68 %; posi-
tive predictive value, PPV = 66.7 %). Strong Mcl-1 expression in 
the different thyroid tissue subsets is summarized in  ●▶  Table 1. 
In addition, to distinguish benign from malignant thyroid tis-
sues, Mcl-1 expression discriminated both FVPTC and CPTC from 
adenomatoid hyperplasia (P  < 0.001), TFA (P  < 0.05) and HT tis-
sues (P  < 0.01). Benign thyroid diseases showed a similar profile 
of Mcl-1 overexpression with no significant difference between 
TFA and adenomatoid hyperplasia specimens ( ●▶  Table 1) or HT 
and normal thyroid tissues. Mcl-1 was also similarly expressed 
among PTC histological variants: 21 (71.4 %) FVPTC were strong 
positive, whereas 2 (66.7 %) tall cell variant and 21 (63.6 %) CPTC 
were Mcl-1 overexpressed. The TCPTC specimens demonstrated 
Mcl-1 and Ki-67 concurrent positivity in 2 out 3 cases studied 
(66.7 %).
Mcl-1 and Ki-67 expression in PTC, benign thyroid disease spec-
imens and normal tissue
The strong Mcl-1 expression and its associations with Ki-67 
staining are summarized in  ●▶  Fig. 2. Ki-67 showed a significantly 
higher proliferative rate in malignant tissues represented by PTC 
(34 %), followed by TFA (19 %), adenomatoid hyperplasia (7.1 %) 
and normal thyroid tissues (P = 0.031), with high specificity 
(85.7 %) and moderate-to-high PPV (65.2 %) and accuracy 
(57.8 %). Strong Mcl-1 and Ki-67 co-expression was identified in 
57.5 % of the PTCs cases vs. 29.1 % of the benign thyroid diseases 
(P < 0.001), enhancing the PPV ( ●▶  Fig. 2).
Correlation of Mcl-1 and Ki-67 expression with clinical, labora-
tory and sonographic data
No significant correlations were found between Mcl-1 expres-
sion and clinicopathological features of malignancy ( ●▶  Table 2). 
Ki-67 expression was correlated with the presence of anti-thy-
roid antibodies in PTCs (P = 0.03). No deaths related to thyroid 
cancer occurred during the follow-up period in spite of the 
Mcl-1 strong positivity.
Discussion
▼
In this study, we observed frequent Mcl-1-positive staining in 
surgically resected PTCs in contrast to benign thyroid diseases 
Table 1 Comparative frequency of immunohistochemical Mcl-1 and Ki-67 overexpression’s in malignant specimens, benign thyroid diseases, Hashimoto’s 
thyroiditis and normal thyroid tissues in a single center.
Malign Benign Thyroid Diseases Peritumoral Total P-value
Apoptotic 
markers
PTC TFA Adenomatoid 
Hyperplasia
HT NOR
(n)/(%) (n)/(%) (n)/(%) (n)/(%) (n)/(%) (n)/(%)
Mcl-1 38/57 (66.7 %) 8/21 (36.3 %) 16/54 (29.1 %) 9/32 (28.1 %) 29/109 (26.6 %) 100/134 (74.6 %) 0.003
Ki-67 15/59 (34 %) 4/21 (19 %) 4/56 (7.1 %) 6/32 (18.8 %) 11/110 (10 %) 40/138 (28.9 %) 0.031
TFA: Thyroid follicular adenoma; HT: Hashimoto thyroiditis; Papillary thyroid carcinoma (PTC); NOR: normal thyroid tissues
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and normal thyroid tissues. A positive correlation between 
Mcl-1 and Ki-67 expression was observed in the malignant spec-
imens (PTC). The anti-apoptotic status of Mcl-1 expression was 
based on IHQ analysis, consistent with previous reports 
[20, 22, 25]. Techniques such as mRNA analysis or western blot 
(WB) were not available in this study; nevertheless, previous 
reports showed higher correlations between these methods and 
IHQ results [23, 36]. Furthermore, the anti-Mcl-1 antibody 
detected the long chain Mcl-1 (isoform 1) protein, holding an 
anti-apoptotic function, consistent with WB results [35, 36], 
supporting our data interpretation and conclusions. None of the 
previous reports discriminated the Mcl-1 isoforms, and all of 
them defined the Mcl-1 overexpression as an anti-apoptotic sta-
tus [20, 22–26].
Apoptosis is the main physiological process of cell death and is 
precisely regulated. The loss of control of any active pathway 
that leads to cell death apoptosis mechanisms may result in an 
imbalance between proliferation and apoptosis, which most 
likely enhances the tumorigenesis process [8, 37, 38]. Some stud-
ies demonstrated the impact of combining malignancy markers 
62 specimens
Mcl-1 strong POSITIVE
Mcl-1 strong (+) / Ki-67
(+) N=29
Mcl-1 strong (+) / Ki-67
(-) N=33
PTC
n=22
Benign thyroid
diseases n=7
PTC
n=16
Benign thyroid
diseases n=17
Sensitivity
Specificity
PPV
NPV
Accuracy
P -value
57.9 %
70.9 %
75.8 %
51.5 %
62.9 %
< 0.05
Fig. 2 Schematic representation of the study 
cohorts and test results of Mcl-1 strong expression 
Ki-67 staining in resected thyroid nodules. PTC 
indicates papillary thyroid cancer; PPV, positive 
predictive value; NPV, negative predictive value.
a b
c d
Fig. 1 Expression of Ki-67 and Mcl-1 in malignant 
and benign thyroid tissues: robust expression of 
Ki-67 a and Mcl-1 c in papillary thyroid cancer 
vs. faint expression of Ki-67 and Mcl-1 in benign 
thyroid diseases, respectively (b, thyroid follicular 
adenoma and d, normal thyroid tissue) (× 200). 
(Color figure available online only)
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to increase the reliability and differential diagnosis of PTCs and 
benign thyroid diseases [11–14, 28–30]. The association between 
the Mcl-1, a cell death blocker, and Ki-67, a proliferation cell 
marker, was not previously described in thyroid reports. In the 
last two decades, there have been limited data in relation to the 
Mcl-1 immunochemical profile in thyroid neoplasms. Branet et 
al. [22] found Mcl-1 overexpression (polyclonal antibody, diluted 
1:800) in 65.2 % (15/23) of PTC specimens in comparison to 
58.3 % (7/12) of TFA cases. The small sample (35 cases) and tech-
nical differences with the Mcl-1 antibodies (dilution and posi-
tivity criteria) most likely led to the divergent results compared 
to the present data.
We verified that almost one-third of benign thyroid diseases 
exhibited robust Mcl-1 positivity, with no difference between 
TFA, adenomatoid hyperplasia and HT specimens. Mcl-1 overex-
pression was characterized as part of PTC immunochemical pro-
file in low-risk cases, which comprised almost 90 % of this 
sample. Thus, the influence of the Mcl-1 expression on features 
of tumor aggressiveness has to be studied in a larger series of 
high-risk DTC cases to determine the clinical impact of this 
marker on patient outcomes. The question becomes do these 
markers have any role in determining whether the PTC will be 
an aggressive lesion or a more indolent growing lesion. The 
TCPTC variant is described as an unfavorable histological sub-
type and may be associated to poor prognosis and survival [2]. 
Our data showed that Mcl-1 was similarly expressed among PTC 
histological variants resulting non-statistical significance. Larger 
series including more aggressive histotypes of PTC are needed to 
determine whether these results are associated with effects on 
the clinical prognosis, recurrence, therapeutic response and sur-
vival rates.
Zhang et al. [23] obtained a high correlation between Mcl-1 and 
Ki-67 expression in resected cervical cancers. Their results 
showed the worst cumulative survival in the patients who pre-
sented with the phenotype Mcl-1( + )/Ki-67( + ) associated with 
advanced histological grade, tumor size and lymph node involve-
ment. Maeta et al. [20] demonstrated the relationship between 
Mcl-1 staining and poor outcomes in almost 70 % of resected 
gastric cancer specimens. Our data showed no correlation 
between clinicopathological and sonographic parameters and 
Mcl-1 expression in PTC cases. We verified the frequent occur-
rence of Mcl-1 expression in PTCs and their close relationship to 
Ki-67 expression. However, our results should not be extrapo-
lated to follicular thyroid carcinomas and should not be used to 
identify individuals with poor prognosis, especially in high-risk 
PTC cases, at this time. Furthermore, our study sought to dem-
onstrate differences between the Mcl-1 immunochemical pro-
file in PTC specimens compared to benign thyroid diseases.
Mcl-1 is regulated at the transcriptional, post-transcriptional 
and translational levels [21, 37, 38]. Further studies are needed 
to clarify the relationship between Mcl-1 expression and clinical 
prognosis in advanced thyroid tumors and its implications for 
the therapeutic use of tyrosine-kinase inhibitors. Sorafenib is a 
multikinase inhibitor that was reported to suppress a number of 
kinases and still acts as a Mcl-1 antagonist [39, 40]. Sorafenib 
inhibits the pro-survival function of Mcl-1 most likely due to 
MAPK (mitogen-activated protein kinase) and inactivation of 
the suppressor tumoral gene Fbw7 [39]. Furthermore, Sorafenib 
inhibits the Jak2/Stat3/Mcl-1 axis, contributing to the apoptotic 
response and cell death based on human anaplastic thyroid car-
cinoma samples [40]. The exact mechanism remains unclear, 
and a large series is needed to define the clinical application of 
Mcl-1 expression in malignant thyroid tumors.
Our results showed a higher proliferative rate for Ki-67 in PTC 
specimens (34 %) consistent with the Saiz et al. [10] results in 19 
PTCs and 10 TFA cases. Erickson et al. verified that Ki-67 expres-
sion could also distinguish TFAs (n = 16) from thyroid follicular 
carcinomas (n = 23), with a significantly higher expression of 
Ki-67 in patients with metastases [13]. In relation to thyroid 
cancer, our study demonstrated that Ki-67 positivity associated 
with Mcl-1 expression increased the PPV for histologically diag-
nosed thyroid malignancy. Kakudo et al. [16] proposed a risk 
stratification of thyroid follicular cell tumors based on the Ki-67 
labeling index, considering high-grade histological features, 
such as tumor necrosis, increased mitoses, and nuclear pleo-
morphism, together with a high Ki-67 labeling index over 10 %, 
as predictors of high-risk DTC and suggested a possible risk for 
anaplastic transformation.
The immunoreactive and cytoplasmic or nuclear apoptotic and 
proliferative cell markers may be helpful in the differential his-
tological diagnosis between malignant and benign thyroid sam-
ples [27–30]. Here, we found an almost 70 % accuracy, sensitivity 
and specificity for Mcl-1 expression for distinguishing benign 
and malignant thyroid tumors. Similarly, Martins et al. [29] 
found a 69 % sensitivity and 75 % specificity for KAP-1 expression 
in the differential diagnosis of benign and malign lesions; Cunha 
et al. [31] found 61.8 % accuracy, 62.1 % sensitivity and 61.4 % 
specificity for FoxP3 staining, whereas Morari et al. [30] found 
89 % sensitivity and 53 % specificity for MUC-1 protein expres-
sion in the histological differentiation between benign and 
malignant thyroid tissues. Based on these results, we suggest 
that Mcl-1 protein expression may help characterize PTC and 
could be an additional tool for routine pathological evaluation.
In summary, using a large series of 282 thyroid tissues including 
59 PTC specimens we demonstrated that Mcl-1 and Ki-67 pro-
tein expression allowed differentiating low-risk PTC from the 
Variables Mcl-1 Total P-value
POSITIVE NEGATIVE
62 72 134
Histologically malignancy diagnosis (n, %) * 40 (62.5 %) 19 (26.3 %) 59 (43.4 %) 0.003
Age > 45 yrs. 35 (57.3 %) 47 (65.2 %) 82 (61.6 %) NS
Female gender (%) 55 (85.9 %) 60 (83.3 %) 115 (84.5 %) NS
Solitary Nodule (%) 38 (60.3 %) 44 (62.9 %) 82 (61.7 %) NS
Size > 2 cm 32 (51.6 %) 47 (70.1 %) 79 (54.2 %) NS
TSH > 1.8 mU/ml 24 (50 %) 20 (41.6 %) 44 (45.8 %) NS
Suspicious ultrasound 46 (77.9 %) 43 (65.2 %) 89 (71.2 %) NS
TNM Stage III/IV 7/38 (18.4 %) 2/19 (10.5 %) 9/57 (15.8 %) NS
TSH: thyroid stimulating hormone. * Significant comparisons between the groups Mcl-1 positive vs. negative; the other comparisons 
displayed no statistical significance (NS); at P < 0.05
Table 2 Correlation between the 
Mcl-1 overexpression and clinico-
pathological features.
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benign thyroid lesions. Based on this data, Mcl-1 expression may 
help differentiate follicular patterned thyroid lesions and char-
acterize thyroid carcinomas. The establishment of association 
between Mcl-1 expression and tumor stage, clinical or patho-
logical feature of aggressiveness or poor outcome requests larger 
studies including intermediate and high-risk thyroid carcinomas 
to determine whether these results are associated with effects 
on the clinical prognosis and therapeutic response.
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